임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
33건 표시
- 3상모집 중· Multiple MyelomaA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
리드: 얀센(J&J)
- 3상모집 중· Colitis, UlcerativeA Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 3상모집 중· Crohn DiseaseA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 3상모집 중· Depressive Disorder, MajorA Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
리드: 얀센(J&J)
- 3상모집 중· Crohn DiseaseA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 3상모집 중· Lupus Erythematosus, SystemicA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
리드: 얀센(J&J)
- 3상모집 중· Depressive Disorder, MajorA Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
리드: 얀센(J&J)
- 3상모집 중· Myasthenia GravisComparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
리드: 얀센(J&J)
- 3상모집 중· Prostatic Neoplasms, Castration-ResistantA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
리드: 얀센(J&J)
- 3상모집 중· Squamous Cell Carcinoma of Head and NeckA Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
리드: 얀센(J&J)
- 3상모집 중· Colitis, UlcerativeA Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
리드: 얀센(J&J)
- 3상모집 중· Non-Muscle Invasive Bladder NeoplasmsA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
리드: 얀센(J&J)
- 3상모집 중· Metastatic Castration-resistant Prostate NeoplasmsA Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
리드: 얀센(J&J)
- 3상모집 중· Leukemia, Myeloid, AcuteA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
리드: 얀센(J&J)
- 3상모집 중· Thrombocytopenia, Neonatal AlloimmuneA Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
리드: 얀센(J&J)
- 3상모집 중· Thrombocytopenia, Neonatal AlloimmuneA Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
리드: 얀센(J&J)
- 3상모집 중· Crohns DiseaseA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
리드: 얀센(J&J)
- 3상모집 중· Depressive Disorder, MajorPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
리드: 얀센(J&J)
- 3상모집 중· Non-Muscle Invasive Bladder NeoplasmsA Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
리드: 얀센(J&J)
- 3상모집 중· Crohn's DiseaseA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
리드: 얀센(J&J)
- 3상모집 중· Multiple MyelomaA Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
리드: 얀센(J&J)
- 3상모집 중· Hemolytic Disease of the Fetus and NewbornA Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
리드: 얀센(J&J)
- 3상모집 중· Myasthenia GravisA Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
리드: 얀센(J&J)
- 3상모집 중· Metastatic Castration-resistant Prostate Cancer (mCRPC)ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
협력: 아스트라제네카, 얀센(J&J)
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.